Findings

What do systematic reviews say?

62 questions · 63 findings · 5 reviews · Pain, Palliative and Supportive Care

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 4.8%GRADE not reported 2 · 3.2%Very low 12 · 19%Low 3 · 4.8%Moderate 19 · 30.2%High 24 · 38.1%

Pregabalin 300 mg or 600 mg vs placebo

mg pregabalin · adults with moderate or severe neuropathic pain

2 findings from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
300 participants
GRADE not reported
Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
600 participants
GRADE not reported

Pregabalin vs placebo

At least 50% reduction in pain · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1874 participants
High

Pregabalin vs placebo

Adverse events as N of participants with at least one adverse event objective · adults with fibromyalgia enrolled in EERW studies

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 687 participants
High

Pregabalin vs placebo

Serious adverse events · adults with fibromyalgia enrolled in EERW studies

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 687 participants
Very low

Pregabalin vs placebo

Death · adults with fibromyalgia enrolled in EERW studies

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 687 participants
Very low

Pregabalin vs placebo

PGIC very much improved · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1869 participants
High

Pregabalin vs placebo

At least 30% reduction in pain · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1874 participants
High

Pregabalin vs placebo

Moderate benefit · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1869 participants
High

Pregabalin vs placebo

Lack of efficacy withdrawal · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1874 participants
High

Pregabalin vs placebo

Withdrawals due to adverse events · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1874 participants
High

Pregabalin vs placebo

Serious adverse events · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1238 participants
Very low

Pregabalin vs placebo

Death · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 3460 participants
Very low

Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit') · adults with fibromyalgia enrolled in EERW studies

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 687 participants
High

Pregabalin vs placebo

Adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Serious adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Participant‐reported pain relief of 30% or greater · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Participant‐reported pain relief of 50% or greater · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Patient Global Impression of Change much or very much improved · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo at end of treatment

At least 50% reduction in pain · patients with fibromyalgia

Pregabalin leads to higher 50% pain reduction compared with placebo at end of treatment (high certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.59 [1.33, 1.9]
5 studies · 3256 participants
High